标题
Targeting tumour-supportive cellular machineries in anticancer drug development
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 13, Issue 3, Pages 179-196
出版商
Springer Nature
发表日期
2014-02-28
DOI
10.1038/nrd4201
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies
- (2015) Katiuscia Bonezzi et al. NEOPLASIA
- A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
- (2013) Jonathan W Goldman et al. BMC CANCER
- Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase
- (2013) Nikolaj H.T. Petersen et al. CANCER CELL
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Killing from the inside
- (2013) Paul Saftig et al. NATURE
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity
- (2013) F. Kopper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- The nucleolus: an emerging target for cancer therapy
- (2013) Nadine Hein et al. TRENDS IN MOLECULAR MEDICINE
- Pharmacological targeting of endoplasmic reticulum stress signaling in cancer
- (2012) Axel H. Schönthal BIOCHEMICAL PHARMACOLOGY
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells
- (2012) Josep Domingo-Domenech et al. CANCER CELL
- Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
- (2012) Megan J. Bywater et al. CANCER CELL
- p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis
- (2012) Angelina V. Vaseva et al. CELL
- Cancer Vulnerabilities Unveiled by Genomic Loss
- (2012) Deepak Nijhawan et al. CELL
- Targeting Cancer Metabolism
- (2012) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
- (2012) A. Villanueva et al. CLINICAL CANCER RESEARCH
- An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
- (2012) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Panobinostat for the treatment of multiple myeloma
- (2012) Paola Neri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice
- (2012) Asfar S. Azmi et al. GASTROENTEROLOGY
- HSP90 and HSP70 Proteins Are Essential for Stabilization and Activation of WASF3 Metastasis-promoting Protein
- (2012) Yong Teng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
- (2012) Ramona Schulz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation
- (2012) Andres J. López-Contreras et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer
- (2012) Sarah B. Goldberg et al. Journal of Thoracic Oncology
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
- (2012) J Etchin et al. LEUKEMIA
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A restricted cell population propagates glioblastoma growth after chemotherapy
- (2012) Jian Chen et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Erratum: ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
- (2012) Weiwei Yang et al. NATURE CELL BIOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
- (2012) Justin M Balko et al. NATURE MEDICINE
- The spliceosome as a target of novel antitumour drugs
- (2012) Sophie Bonnal et al. NATURE REVIEWS DRUG DISCOVERY
- Erratum: Interfacial inhibitors: targeting macromolecular complexes
- (2012) Yves Pommier et al. NATURE REVIEWS DRUG DISCOVERY
- Ruxolitinib
- (2012) Ruben A. Mesa et al. NATURE REVIEWS DRUG DISCOVERY
- Cancer biomarkers: selecting the right drug for the right patient
- (2012) Gary J. Kelloff et al. NATURE REVIEWS DRUG DISCOVERY
- New insights into the regulation and cellular functions of the ARP2/3 complex
- (2012) Jeremy D. Rotty et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs
- (2012) D. J. Adams et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
- (2012) H. M. Stern Science Translational Medicine
- Engineering a Prostate-Specific Membrane Antigen-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy
- (2012) S. R. Denmeade et al. Science Translational Medicine
- The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation
- (2012) Biljana Culjkovic-Kraljacic et al. Cell Reports
- Small Molecule Inhibition of RISC Loading
- (2011) Grace S. Tan et al. ACS Chemical Biology
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
- (2011) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Oncogene-Induced Mitotic Stress: p53 and pRb Get Mad Too
- (2011) Marcos Malumbres CANCER CELL
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
- (2011) Thomas De Raedt et al. CANCER CELL
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- Estrogen-Dependent Gene Transcription in Human Breast Cancer Cells Relies upon Proteasome-Dependent Monoubiquitination of Histone H2B
- (2011) T. Prenzel et al. CANCER RESEARCH
- Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened Antagonists
- (2011) C. Metcalfe et al. CANCER RESEARCH
- Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
- (2011) Florian Grebien et al. CELL
- An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme
- (2011) Derek F. Ceccarelli et al. CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- (2011) D Li et al. CELL DEATH AND DIFFERENTIATION
- Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer
- (2011) F. Pettersson et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
- (2011) Meir Wetzler et al. CURRENT PHARMACEUTICAL DESIGN
- Proteotoxic stress of cancer: Implication of the heat-shock response in oncogenesis
- (2011) Chengkai Dai et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study
- (2011) Raymond J. Osborne et al. JOURNAL OF CLINICAL ONCOLOGY
- Occurrence of Multiple Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- (2011) Gregory T. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
- (2011) Neal Ready et al. Journal of Thoracic Oncology
- Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
- (2011) A Deshpande et al. LEUKEMIA
- Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
- (2011) D. Li et al. MOLECULAR CANCER RESEARCH
- Distinct Autophagosomal-Lysosomal Fusion Mechanism Revealed by Thapsigargin-Induced Autophagy Arrest
- (2011) Ian G. Ganley et al. MOLECULAR CELL
- Chromatin and the DNA damage response: The cancer connection
- (2011) Martijn S. Luijsterburg et al. Molecular Oncology
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Selective killing of cancer cells by a small molecule targeting the stress response to ROS
- (2011) Lakshmi Raj et al. NATURE
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
- (2011) Hiroyuki Inuzuka et al. NATURE
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance
- (2011) Jiri Lukas et al. NATURE CELL BIOLOGY
- Inhibition of proteasome deubiquitinating activity as a new cancer therapy
- (2011) Pádraig D'Arcy et al. NATURE MEDICINE
- Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
- (2011) Coralie Dorard et al. NATURE MEDICINE
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11
- (2011) Masato Sasaki et al. NATURE MEDICINE
- EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
- (2011) Michela Garofalo et al. NATURE MEDICINE
- Autophagy as a target for anticancer therapy
- (2011) Filip Janku et al. Nature Reviews Clinical Oncology
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
- (2011) Matilde Murga et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes
- (2011) Ulrike Beyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
- (2011) T. N. Chonghaile et al. SCIENCE
- Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
- (2010) Xing Zeng et al. CANCER CELL
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
- (2010) Boris G. Wilson et al. CANCER CELL
- Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
- (2010) Mark A. Gregory et al. CANCER CELL
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor
- (2010) Wei-Lien Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Valproic Acid in the Complex Therapy of Malignant Tumors
- (2010) J. Hrebackova et al. CURRENT DRUG TARGETS
- Mitotic drug targets
- (2010) Phillip Kaestner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- (2010) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new
- (2010) Kyle A Furge et al. LANCET ONCOLOGY
- Origins and Evolution of Antibiotic Resistance
- (2010) J. Davies et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- Cellular Metabolic Stress: Considering How Cells Respond to Nutrient Excess
- (2010) Kathryn E. Wellen et al. MOLECULAR CELL
- The Nucleolus under Stress
- (2010) Séverine Boulon et al. MOLECULAR CELL
- Enhancement of proteasome activity by a small-molecule inhibitor of USP14
- (2010) Byung-Hoon Lee et al. NATURE
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Towards patient-based cancer therapeutics
- (2010) Stuart L Schreiber et al. NATURE BIOTECHNOLOGY
- Targeting tumour metabolism
- (2010) NATURE REVIEWS DRUG DISCOVERY
- HSP90 at the hub of protein homeostasis: emerging mechanistic insights
- (2010) Mikko Taipale et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation
- (2010) Gabriel A. Roybal et al. NUCLEIC ACIDS RESEARCH
- Spliceosome Structure and Function
- (2010) C. L. Will et al. Cold Spring Harbor Perspectives in Biology
- Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
- (2009) S. Assouline et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly
- (2009) Hsiao-Chun Huang et al. CANCER CELL
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
- (2009) S. C. Mutka et al. CANCER RESEARCH
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
- (2009) D. Milojkovic et al. CLINICAL CANCER RESEARCH
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Dicer1 functions as a haploinsufficient tumor suppressor
- (2009) M. S. Kumar et al. GENES & DEVELOPMENT
- Hsp90 Regulates the Function of Argonaute 2 and Its Recruitment to Stress Granules and P-Bodies
- (2009) Justin M. Pare et al. MOLECULAR BIOLOGY OF THE CELL
- A Small Molecule Inhibitor of Inducible Heat Shock Protein 70
- (2009) J. I-Ju Leu et al. MOLECULAR CELL
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Cancer stem cells: mirage or reality?
- (2009) Piyush B Gupta et al. NATURE MEDICINE
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- (2009) Leandro C Cerchietti et al. NATURE MEDICINE
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
- (2009) Rowan T. Chlebowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
- (2009) Charles M. Rudin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mimicking the BH3 domain to kill cancer cells
- (2009) T Ni Chonghaile et al. ONCOGENE
- Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells
- (2009) Aniek Janssen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
- (2009) T. Hitosugi et al. Science Signaling
- Histone methyltransferases in cancer
- (2009) Mareike Albert et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
- (2008) S. A. Eccles et al. CANCER RESEARCH
- Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors
- (2008) Alfonso Duenas-Gonzalez et al. CANCER TREATMENT REVIEWS
- An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer
- (2008) Lars Zender et al. CELL
- DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
- (2008) S. Ashwell et al. CLINICAL CANCER RESEARCH
- Tumor Stroma as a Target in Cancer
- (2008) F. Ahmed et al. CURRENT CANCER DRUG TARGETS
- Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes
- (2008) M. Kwon et al. GENES & DEVELOPMENT
- Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging
- (2008) R. I. Morimoto GENES & DEVELOPMENT
- The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
- (2008) T. Terzian et al. GENES & DEVELOPMENT
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
- (2008) Carlo Stresemann et al. INTERNATIONAL JOURNAL OF CANCER
- Pyruvate kinase M2 is a phosphotyrosine-binding protein
- (2008) Heather R. Christofk et al. NATURE
- A paracrine requirement for hedgehog signalling in cancer
- (2008) Robert L. Yauch et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
- Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
- (2008) Inki Kim et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?
- (2008) Witold Filipowicz et al. NATURE REVIEWS GENETICS
- Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
- (2008) S. Varambally et al. SCIENCE
- Why does cytotoxic chemotherapy cure only some cancers?
- (2008) Philip Savage et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started